The first canser that we focused on, and did this for a couple of reasons to at least itwas the cancer that the fda wanted us to focus on. The deadly brain cancer, gleo blasdoma, or g b m. It's now over 35 phase three trials of drugs have all failed in this disease. In our trial, the control group who received the therape i just described had a five year survival of about five %. When we applied tumer treating fields radiation with the t m z, we increase the five years survival from five% to about 13%. We're doing a lot of things on the side right now to improve the pre-clinical engineering models

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode